ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer

Post author:admERY
Post published:July 20, 2015
Post category:Newsroom

ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.

You Might Also Like

General Meeting to be held on June 28, 2018 and Availability of Related Materials

ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia

ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference